<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729573</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-003B</org_study_id>
    <secondary_id>10709</secondary_id>
    <nct_id>NCT00729573</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density Substudy - An Ancillary Study to MTN-003</brief_title>
  <official_title>Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Microbicide Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The MTN-003 HIV prevention study include the use of microbicides, substances that kill
      microbes, and tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil
      fumarate (FTC/TDF) - oral, FDA-approved, anti-HIV drugs. The purpose of this study is to
      determine if taking daily TDF and FTC/TDF as a part of the study MTN-003 has an effect on
      bone mineral density (BMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of tenofovir on bone mineral density (BMD) has not yet been studied and is of
      potential concern. The purpose of this study is to determine the changes in BMD among
      individuals receiving TDF and FTC/TDF compared with a placebo.

      This substudy will enroll individuals currently participating in MTN-003. The expected
      duration of participation for each participant is approximately 48 months. Study treatment
      will be provided by MTN-003. Study treatment will not be provided by this substudy.

      Study visits will occur every 6 months after enrollment. A nutrition assessment, physical
      activity history, and urine and blood collection will occur at all visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in bone mineral density</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in nutrition</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">518</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>200 mg/300 mg tabletas a part of MTN-003</description>
    <arm_group_label>1</arm_group_label>
    <other_name>FTC/TDF</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate placebo</intervention_name>
    <description>placebo tablet as a part of MTN-003</description>
    <arm_group_label>1</arm_group_label>
    <other_name>FTC/TDF placebo</other_name>
    <other_name>Truvada placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300 mg tablet as a part of MTN-003</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate placebo</intervention_name>
    <description>placebo tablet as a part of MTN-003</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TDF placebo</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sexually active, HIV-uninfected women who are currently enrolled in MTN-003
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in MTN-003

          -  Randomized to oral study product in MTN-003 within 14 days prior to study entry

        Exclusion Criteria:

          -  Medical condition known to affect bone or taking any medication known to affect bone.
             More information on this criterion can be found in the protocol.

          -  Permanently discontinued from oral study product in MTN-003 prior to study entry

          -  Any condition that, in the opinion of the investigator, would interfere with the study

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon A. Riddler, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MU-JHU Research Collaboration (MUJHU CARE LTD) CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke South CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zengeza CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spilhaus CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://www.mtnstopshiv.org/</url>
    <description>Click here for the Microbicide Trials Network Web site</description>
  </link>
  <reference>
    <citation>Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006 Feb 28;20(4):543-51.</citation>
    <PMID>16470118</PMID>
  </reference>
  <reference>
    <citation>Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.</citation>
    <PMID>18328009</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbicide</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Bone Mineral Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

